Neutrophil gelatinase-associated lipocalin immunoexpression in colorectal carcinoma: A stage-specific prognostic factor?

Oncology Letters

Volumn 1, Issue 6, 2010, Pages 1089-1096

  Barresi, Valeria ^a   Lucianò, Roberta ^a   Vitarelli, Enrica ^a   Labate, Agata ^a   Tuccari, Giovanni ^a   Barresi, Gaetano ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Colorectal cancer; Iron; Neutrophil gelatinase associated lipocalin; Prognosis; TNM stage

Indexed keywords

NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CARCINOMA; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PROGNOSIS; PROTEIN EXPRESSION;

EID: 77957943361     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2010.191     Document Type: Article

References (31)

1. Landis H, Murray T, Bolden S and Wingo PA: Cancer statistics. Cancer J Clin 49: 8-31, 1999.
2. Wiggers T, Arends JW, Schutter B, Volovics L and Bosman FT: A multivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer 61: 386-389, 1988.
3. Wu XC, Chen VW, Steele B, Ruiz B, Fulton J, Liu L, CarozzaSE and Greenlee R: Subsite-specific incidence rate and stage of disease in colorectal cancer by race, gender, and age group. Cancer 92: 2547-2554, 2001.
4. Di Gregorio C, Benfatti P, Losi L, Roncucci L, Rossi G, Ponti G, Marino M, Pedroni M, Scarselli A, Roncari B and PonzdeLeonM: Incidence and survival of patients with Dukes'A (stages T1 and T2) colorectal carcinoma: a 15-year population-based study. Int J Colorectal Dis 20: 147-154, 2005.
5. Cowland JB and Borregaard N: Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 45: 17-23, 1997.
6. Bratt T: Lipocalins and cancer. Biochim Biophys Acta 1482: 318-326, 2000.
7. Yang J, Goetz D, Li JY, Wang W, Mori K and Setlik D: An iron delivery pathway mediated by a lipocalin. Mol Cell 10: 1045-1056, 2002.
8. Goetz DH, Willie ST, Arme RS, Bratt T, Borregaard N and Strong RK: Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry 39: 1935-1941, 2000.
9. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, RaymondKN and Strong RK: The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 10: 1033-1043, 2002.
10. Gwira JA, Wei F, Ishibe S, Ueland JM, Barasch J and CantleyLG: Expression of neutrophil associated-gelatinase lipocalin regulates epithelial morphogenesis in vitro. J Biol Chem 280: 7875-7882, 2005.
11. Bolignano D, Donato V, Lacquaniti A, et al: Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett 288: 10-16, 2010.
12. Hannai J, Mammoto T, Seth P, Mori K, Karumanchi SA, Barasch J and Sukhatme VP: Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem 280: 3641-3647, 2005.
13. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maas N and Friedl A: Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 108: 389-397, 2008.
14. Iannetti A, Pacifico F, Acquaviva R, et al: The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc Natl Acad Sci USA 105: 14058-14063, 2008.
15. Barresi V, Ieni A, Bolignano D, Magno C, Buemi M and BarresiG: Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: correlation with histotype and histological grade. Oncol Rep 24: 305-310, 2010.
16. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, SehestedM and Kjeldsen L: Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 38: 414-420, 1996.
17. Zhang XF, Zhang Y, Zhang XH, Zhou SM, Yang GG, WangOC, Guo GL, Yang GY and Hu XQ: Clinical significance of Neutrophil gelatinase-associated lipocalin (NGAL) expression in primary rectal cancer. BMC Cancer 91: 34, 2009.
18. Hu L, Hittelman W, Lu T, Ji P, Arlinghaus R, Shmulevich I, Hamilton SR and Zhang W: NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest 89: 531-548, 2009.
19. Friedl A, Stoesz SP, Buckley P and Gould MN: Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J 31: 433-441, 1999.
20. Moniaux N, Chakraborty S, Yalniz M, et al: Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer 98: 1540-1547, 2008.
21. Kubben FJ, Sier CF, Hawinkels LJ, et al: Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer 43: 1869-1876, 2007.
22. Zhang H, Xu L, Xiao D, et al: Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion. J Clin Pathol 60: 555-561, 2007.
23. Devireddy LR, Gazin C, Zhu X and Green MR: A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 23: 1293-1305, 2005.
24. Toyokuni S: Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 100: 9-16, 2009.
25. Le NTV and Richardson DN: The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 1603: 3146, 2002.
26. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL and MosesMA: The matrix metallo-proteinase-9/neutrophil gelatinase associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 11: 5390-5395, 2005.
27. Lee S, Jilani SM, Nikolova GV, Carpizo D and Iruela-Arispe M: Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169: 681-691, 2005.
28. Yan L, Borregaard N, Kjeldsen L and Moses MA: The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 276: 37258-37265, 2001.
29. Leng X, Ding T, Lin H, et al: Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res 69: 8579-8784, 2009.
30. Buss JL, Greene BT, Turner J, Torti FM and Torti SV: Iron chelators in cancer chemotherapy. Curr Top Med Chem 4: 1623-1635, 2004.
31. Jones DT, Trowbridge IS and Harris AL: Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate. Cancer Res 66: 2749-2756, 2006.